Month: March 2018

Is plagiarism a problem in economics? Survey of editors says … yes

Gary Hoover

In 2004, a survey of editors of economic journals found 3 out of 10 had seen at least one case of plagiarism within the past year. More than a decade later, has the problem gotten better? Or worse? Gary Hoover at the University of Oklahoma, who co-authored the 2004 paper, decided to revisit the issue by resurveying editors in economics, along with others working in different fields. What he found — and reported in Social Science Quarterly — was plagiarism is still a problem, which economists want to address.

Retraction Watch: Why did you want to revisit the findings from the 2004 survey of editors in economics 10 years later?

Continue reading Is plagiarism a problem in economics? Survey of editors says … yes

Data in biofuel paper “had either been grossly misinterpreted or fabricated”

A biology journal has retracted a 2011 paper after the University of California, Los Angeles determined that the data in three figures “cannot be supported.”

In February, the journal Applied and Environmental Microbiology retracted the paper, which explores efforts to engineer bacteria to convert plant biomass into biofuel.

Claudia Modlin, assistant director of UCLA’s Office of Research Policy and Compliance, told Retraction Watch that the university informed the journal about the issues last October, after reviewing the work. Continue reading Data in biofuel paper “had either been grossly misinterpreted or fabricated”

Want to tell if a paper has been retracted? Good luck

Caitlin Bakker

Nowadays, there are many ways to access a paper — on the publisher’s website, on MEDLINE, PubMed, Web of Science, Scopus, and other outlets. So when the publisher retracts a paper, do these outlets consistently mark it as such? And if they don’t, what’s the impact? Researchers Caitlin Bakker and Amy Riegelman at the University of Minnesota surveyed more than one hundred retractions in mental health research to try to get at some answers, and published their findings in the Journal of Librarianship and Scholarly Communication. We spoke to Bakker about the potential harm to patients when clinicians don’t receive consistent notifications about retracted data.

Retraction Watch: You note: “Of the 144 articles studied, only 10 were represented as being retracted across all resources through which they were available. There was no platform that consistently met or failed to meet all of [the Committee on Publication Ethics (COPE)’s] guidelines.” Can you say more about these findings, and the challenges they may pose?

Continue reading Want to tell if a paper has been retracted? Good luck

Caught Our Notice: No retraction for “likely fraudulent” study

Title: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease

What Caught Our Attention:  In a letter to the editor, researchers led by Mark Bolland recently outlined the many reasons why a study by Yoshihiro Sato and colleagues in The American Journal of Medicine was “unreliable,” including evidence that the patient numbers were not achievable as described, and inconsistencies and errors in the study data. And let’s not forget a 2016 analysis (co-authored by Bolland) which cast doubt on Sato’s body of work, suggesting that more than 30 of his papers could be problematic. Continue reading Caught Our Notice: No retraction for “likely fraudulent” study

When a journal is delisted, authors pay a price

Shocked, confused, disappointed — these are the reactions of authors who recently published in a cancer journal that was delisted by a company that indexes journals.

Recently, Clarivate Analytics announced it would discontinue indexing Oncotarget after the first few issues of 2018 — as a result, the journal would not receive a current impact factor. The company did not tell us a specific reason why, simply saying it “no longer meets the standards necessary for continued coverage.” Last year, the journal was also removed from the U.S. government biomedical research database MEDLINE, also with no explanation. (At the time, the National Library of Medicine’s Associate Director for Library Operations told us readers who are familiar with the guidelines MEDLINE follows when deselecting journals “can draw their own conclusions” as to why Oncotarget was removed.)

After we covered Clarivate’s decision to delist Oncotarget, many posted comments on the story, including suggestions the move could hurt authors who submitted papers before the announcement. (Some comments also appeared to be versions of the same request that the journal be indexed through January 15.)

We reached out to many of the corresponding authors on papers in the January 26 issue, the seventh issue published in 2018. Many are based at leading institutions around the world; all had submitted their manuscripts months ago. Some noted that they were surprised by the decision, as the review process appeared quite rigorous; some told us that if they’d known the journal was going to be delisted, they would not have submitted their papers there.

Continue reading When a journal is delisted, authors pay a price

Probe into Carlo Croce reached “defensible and reasonable” decisions, says external review

An independent analysis of how The Ohio State University reviewed allegations of misconduct against a high-profile cancer researcher has found that the institution “complied with applicable law and with relevant institutional policies and reached reasoned and supportable conclusions.”

The review follows numerous allegations of research misconduct against Carlo Croce, described in a March 8 story in the New York Times. According to the Times article, Croce has been the subject of multiple investigations; at least five of those inquiries from OSU cleared him of wrongdoing. 

Croce has denied the allegations, and is now suing the New York Times and an outside researcher who served as a key source in the story. As a result of the story, however, OSU — where Croce is based — told us last year it had “launched an independent review of our systems for ensuring research integrity.”

Continue reading Probe into Carlo Croce reached “defensible and reasonable” decisions, says external review

Retraction count for Italian researcher swells to 15 as five papers fall

A researcher who is facing a criminal investigation in Italy for research misconduct has seen five more papers retracted, for a total of 16 15.

Molecular and Cellular Biology has retracted four papers published between 1987 to 2001 by Alfredo Fusco, a cancer researcher in Italy; the Journal of Virology retracted one 1985 paper. Fusco was first author on two papers and last author on three. Both journals are published by The American Society for Microbiology (ASM), which issued identical retraction notices for all five papers, mentioning “evidence of apparent manipulation and duplication.”

Carlo Croce, a cancer researcher now at the Ohio State University, who has been dogged by misconduct allegations, co-authored one of the papers.  Croce now has eight retractions.

Here’s the notice presented for all five retractions: Continue reading Retraction count for Italian researcher swells to 15 as five papers fall

Weekend reads: 20th anniversary of a fraud; uses and misuses of doubt; how common is scooping?

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, would you consider a tax-deductible donation to support it? 

The week at Retraction Watch featured the story of how two highly cited papers turned out to be wrong; a big prize for a researcher who has been dogged by allegations; and a mass resignation at a journal. Here’s what was happening elsewhere: Continue reading Weekend reads: 20th anniversary of a fraud; uses and misuses of doubt; how common is scooping?

A “GROSS CASE OF PLAGIARISM:” How did one Elsevier journal plagiarize another?

Nicholas Peppas

When Nicholas Peppas, chair of engineering at the University of Texas at Austin, discovered one of his papers had been plagiarized, he decided to “go public!”

On February 27, Peppas tweeted about a “gross case of plagiarism:” He alleged a 2013 review published in Saudi Pharmaceutical Journal had directly copied sections of his 2011 review in Advanced Drug Delivery Reviews—both published by Elsevier. (The tweet includes a side-by-side image of a section of the two texts.) Continue reading A “GROSS CASE OF PLAGIARISM:” How did one Elsevier journal plagiarize another?

“Ethical shades of gray:” 90% of researchers in new health field admit to questionable practices

Anthony R. Artino, Jr.

It’s always interesting to know how many researchers in any given field engage in so-called questionable research practices that don’t rise to the level of out-and-out fraud: honorary authorship, citing articles they don’t read, choosing reference lists that would please editors or reviewers, for instance. And when the researchers work in a field with potential health implications, the findings are even more compelling. Lauren Maggio and Anthony R. Artino, Jr. from the Uniformed Services University spoke to us recently about the findings from their survey (posted in bioarXiv) of health professions education researchers, a relatively new field that studies how future health professionals are trained.

Retraction Watch: You note that 90% of the people who volunteered to complete the survey admitted to at least one questionable research practice. Was that surprising?

Continue reading “Ethical shades of gray:” 90% of researchers in new health field admit to questionable practices